Navigation Links
Neurocrine Biosciences Reports Fourth Quarter and Year-End 2008 Results
Date:2/3/2009

ing agreement on a registration plan with the Food and Drug Administration (FDA).

The Company is also currently conducting two additional randomized placebo-controlled Phase IIb clinical trials. The primary clinical endpoint for both of these trials is a reduction in pelvic pain associated with endometriosis, utilizing a Numeric Rating Scale. The first Phase IIb trial includes the Company's selected commercial formulation tablet in two once daily doses, (150 mg and 250 mg); this trial has completed the initial three-month placebo controlled dosing regimen and continues with an additional three-months of elagolix treatment. The Company will report top-line results from the first three months of treatment at the end of the first quarter of 2009. The second trial is a four arm comparator trial of two once daily doses of elagolix (150 mg and 250 mg), placebo or leuprolide depot. This trial is being conducted in Central Eastern Europe and is currently enrolling. Top-line data from this 3-month double-blind trial of approximately 180 patients is expected to be available in the third quarter of 2009.

The Company expects to hold an end of Phase II meeting with the FDA in late 2009.

Neurocrine is also investigating the potential of certain GnRH antagonists in treating other hormone-dependent diseases in men's and women's health.

Corticotropin Releasing Factor (CRF1) Receptor Antagonists for Anxiety/Depression and IBS

The CRF collaboration between Neurocrine and GSK has identified multiple unique high affinity and selective antagonists for the CRF1 receptor that are currently in clinical development for mood disorders and irritable bowel syndrome (IBS).

In a double-blind, randomized, placebo controlled, multiple dose study to evaluate the safety and efficacy of the CRF1 receptor antagonist, 876008, in approximately 130 patients with IBS, no statistically signif
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Webcast Alert: Neurocrine Announces 1Q08 Financial Results
2. Neurocrine Announces Closing of $109 Million Sale and Leaseback Agreement for its Real Estate Assets
3. Neurocrine Biosciences to Present at the CIBC World Markets 18th Annual Healthcare Conference
4. Enlight Biosciences Expands to direct up to $52 Million to Transformational Enabling Technologies
5. New Jersey-Based Biotech Start-Up Nexomics Biosciences Gets Off the Ground
6. URMC, Lighthouse Biosciences Awarded U.S. Patent for Diagnostic Technology
7. URMC, Lighthouse Biosciences awarded US patent for diagnostic technology
8. Abbott Completes Acquisition of Ibis Biosciences, a Subsidiary of Isis
9. CeloNova BioSciences Receives FDA Market Approval for Embozene(TM) Color-Advanced Microspheres Embolization Platform
10. Pressure BioSciences, Inc. Announces Restructuring, Significant Cost Reduction Initiatives, and Sharpened Focus
11. Alexander R. Giaquinto, Ph.D., Joins Regado Biosciences as Senior Vice President of Regulatory Affairs and Quality Assurance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2015)... "Necrorun" was featured on NewsWatch as part of its ... and coolest applications on the market for iOS, Android, ... technology expert, conducted the app review and shared with ... with knights, nature, and peasants. , The first ... Eurogamer. The popularity of these games grew over the ...
(Date:3/28/2015)... Emergency Medical Care (EMC), a New ... recently commemorated its three-year anniversary of being the only ... to 24-hour urgent care, Emergency Medical Care offers its ... time, Emergency Medical Care’s Urgent Care NYC ... eye injuries, ear infections, fevers, insect bites, burns, animal ...
(Date:3/28/2015)... March 28, 2015 One in three ... to research presented today at the American Orthopaedic Society ... study examined the long term success of surgery for ... examined survey data from 242 patients who underwent ACL ... P. Roe, MBBS, FRACS, from North Sydney Orthopaedic and ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 Andrew Hawley of ... 1960's Who psychedelic concert posters. The Who and the Doors ... on August 2, 1968. According to Hawley, “The Who toured ... concert halls and college campuses. Perhaps the most famous Who ... Jim Morrison and the Doors on August 2, 1968 at ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 Designers and ... new overlay entitled Scratches 5K from Pixel Film Studios. ... effects to any media inside Final Cut Pro X” ... Corporate saves time and is an effective tool for ... FCPX Overlay Scratches 5K's intuitive grunge overlays. Simply drag ...
Breaking Medicine News(10 mins):Health News:A Grim Endless Runner Game Was Featured on NewsWatch Television on January 30, 2015 2Health News:Emergency Medical Care Celebrates Three Years of 24/7 Walk-In Urgent Care Services 2Health News:Young Athletes at Greater Risk for Re-Injury after ACL Surgery 2Health News:Avid Collector from Vintage Rock Posters, Inc. Announces His Search For Original 1960's Who Psychedelic Concert Posters. 2Health News:Pixel Film Studios Unveiled Scratches 5k for Final Cut Pro X Editors 2
... Practitioners of clinical medicine are familiar with learning ... minimize learning-curve effects on clinical care. Because similar learning ... researchers at Duke University Medical Center studied the phenomenon ... trial. Their findings point to ways to improve the ...
... Researchers seeking to learn more about stroke by studying ... this week releasing new findings that they hope will aid ... cancer. The Japanese team is reporting in a ... that they are optimistic that inhibiting a protein found on ...
... of prostate cell that has been largely ignored by cancer ... new studies by Howard Hughes Medical Institute (HHMI) scientists and ... his colleagues at the University of California, Los Angeles (UCLA) ... tumors in the prostate gland. Their studies, which were unveiled ...
... would assume that body-checking -- intentionally slamming an opponent against ... hockey. But they would be wrong. Findings from a ... of young hockey players, show that 66 percent of overall ... posts, colliding with teammates or being hit by a puck. ...
... The recent discovery of more than a thousand genes ... up a new approach to understanding the function and ... made even more compelling with the finding that dozens ... commonly mutated gene in cancer), suggesting that this class ...
... history of male breast cancer perceive themselves to be at ... a family history of female breast cancer; however those with ... know about or seek genetic testing than those with a ... led by researchers at the University of Louisville,s James Graham ...
Cached Medicine News:Health News:Clinical trials can be improved by managing the learning curve 2Health News:Clinical trials can be improved by managing the learning curve 3Health News:Snake venom studies yield insights for development of therapies for heart disease and cancer 2Health News:Snake venom studies yield insights for development of therapies for heart disease and cancer 3Health News:Snake venom studies yield insights for development of therapies for heart disease and cancer 4Health News:A new ground zero for prostate cancer 2Health News:A new ground zero for prostate cancer 3Health News:Most youth hockey injuries caused by accidents, not checking, UB study shows 2Health News:'Linc-ing' a noncoding RNA to a central cellular pathway 2Health News:Male breast cancer in family leads to high perception of risk, low likelihood of genetic counseling 2Health News:Male breast cancer in family leads to high perception of risk, low likelihood of genetic counseling 3
(Date:3/27/2015)... 2015 /CNW/ - Covalon Technologies Ltd. (the "Company" or ... announced the issuance of an aggregate of 30,000 stock ... an aggregate of 120,500 stock options to employees and ... over three years and will be exercisable for a ... $1.40 per stock option. About Covalon ...
(Date:3/27/2015)... Telbec/ - Russell Williams , President of ... the 2015-2016 Quebec Budget, noting the fiscal discipline and ... industry. However, the association is concerned about the decline ... government,s intent to strive for a balanced budget this ... Quebec,s economic development is encouraging," said ...
(Date:3/27/2015)... March 27, 2015   Cypher Genomics, Inc., ... new data showing that, compared to a panel ... provided highly equivalent interpretations of whether certain genetic ... so in a fraction of the time. Cypher,s ... more comprehensive genetic analysis in non-invasive prenatal testing ...
Breaking Medicine Technology:Covalon Announces Issuance of Stock Options 2Quebec 2015-2016 Budget: Rx&D welcomes fiscal discipline and biopharma working group, but the decrease in government spending on medicines is questioned 2Quebec 2015-2016 Budget: Rx&D welcomes fiscal discipline and biopharma working group, but the decrease in government spending on medicines is questioned 3New Data at ACMG Shows Cypher's Software Can Automate Interpretation of Genetic Variants to Advance Non-invasive Prenatal Testing 2New Data at ACMG Shows Cypher's Software Can Automate Interpretation of Genetic Variants to Advance Non-invasive Prenatal Testing 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: